MA53904A - Composés contenant du deutérium - Google Patents

Composés contenant du deutérium

Info

Publication number
MA53904A
MA53904A MA053904A MA53904A MA53904A MA 53904 A MA53904 A MA 53904A MA 053904 A MA053904 A MA 053904A MA 53904 A MA53904 A MA 53904A MA 53904 A MA53904 A MA 53904A
Authority
MA
Morocco
Prior art keywords
compounds containing
containing deuterium
deuterium
compounds
Prior art date
Application number
MA053904A
Other languages
English (en)
French (fr)
Inventor
Fredrik Lehmann
Original Assignee
Oncopeptides Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1816998.7A external-priority patent/GB201816998D0/en
Priority claimed from GBGB1909695.7A external-priority patent/GB201909695D0/en
Application filed by Oncopeptides Ab filed Critical Oncopeptides Ab
Publication of MA53904A publication Critical patent/MA53904A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA053904A 2018-10-18 2019-10-17 Composés contenant du deutérium MA53904A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1816998.7A GB201816998D0 (en) 2018-10-18 2018-10-18 Compounds
GBGB1909695.7A GB201909695D0 (en) 2019-07-05 2019-07-05 Compounds

Publications (1)

Publication Number Publication Date
MA53904A true MA53904A (fr) 2021-08-25

Family

ID=68290247

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053904A MA53904A (fr) 2018-10-18 2019-10-17 Composés contenant du deutérium

Country Status (19)

Country Link
US (2) US12152087B2 (https=)
EP (1) EP3866931B1 (https=)
JP (2) JP7603199B2 (https=)
KR (1) KR102848971B1 (https=)
CN (1) CN112930214B (https=)
AU (1) AU2019362389B2 (https=)
BR (1) BR112021007060A2 (https=)
CA (1) CA3116198A1 (https=)
DK (1) DK3866931T3 (https=)
ES (1) ES2942468T3 (https=)
FI (1) FI3866931T3 (https=)
HU (1) HUE061801T2 (https=)
IL (1) IL282231B2 (https=)
MA (1) MA53904A (https=)
MX (1) MX2021004474A (https=)
PL (1) PL3866931T3 (https=)
SG (1) SG11202103726RA (https=)
WO (1) WO2020079165A1 (https=)
ZA (1) ZA202102492B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201905477D0 (en) * 2019-04-17 2019-05-29 Oncopeptides Ab Novel formulations
EP4347615B1 (en) * 2021-06-01 2025-05-21 Synthon B.V. Process for making melflufen or a salt thereof
GB202109895D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
GB202109894D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
WO2023281007A1 (en) 2021-07-08 2023-01-12 Oncopeptides Ab Melflufen for use in the treatment of multiple myeloma
GB202109896D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
GB202204171D0 (en) 2022-03-24 2022-05-11 Oncopeptides Ab Novel formulations
WO2026057823A1 (en) * 2024-09-13 2026-03-19 Oncopeptides Ab Bis-chloroethylamino derivatives for treating leukemia

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002202D0 (sv) 2000-06-13 2000-06-13 Karolinska Innovations Ab New peptides
WO2010044981A2 (en) 2008-09-18 2010-04-22 Auspex Pharmaceutical ,Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
CA2801061A1 (en) 2010-06-01 2011-12-08 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
CA3024230C (en) * 2011-04-28 2022-10-18 Oncopeptides Ab Lyophilized preparation of cytotoxic dipeptides
CN104684555A (zh) 2012-09-18 2015-06-03 奥斯拜客斯制药有限公司 囊泡单胺转运体2的氘化苯并喹啉抑制剂的制剂药代动力学
WO2014065751A1 (en) * 2012-10-26 2014-05-01 Oncopeptides Ab Lyophilized preparations of melphalan flufenamide
EA202091397A1 (ru) 2013-01-31 2020-09-04 Ауспекс Фармацетикалс, Инк. Бензохинолоновые ингибиторы vmat2
KR20150115807A (ko) * 2013-02-05 2015-10-14 임파 악치엔게젤샤프트 위치-특이적 비대칭 중수소 풍부 카테콜아민 유도체 및 상기 화합물을 포함하는 약제
EA201791466A1 (ru) 2013-12-03 2017-11-30 Оспекс Фармасьютикалз, Инк. Способы получения соединений бензохинолина
CN110229159B (zh) * 2013-12-18 2021-08-24 康塞特医药品有限公司 卢索替尼的氘代衍生物
HRP20221106T1 (hr) 2015-03-06 2022-11-25 Auspex Pharmaceuticals, Inc. Postupci liječenja abnormalnih nevoljnih poremećaja pokreta
GB201507903D0 (en) * 2015-05-08 2015-06-24 Oncopeptides Ab Process for preparation of nitrogen mustard derivatives
GB201521217D0 (en) * 2015-12-01 2016-01-13 Oncopeptides Ab Dosage regimens

Also Published As

Publication number Publication date
US20210388024A1 (en) 2021-12-16
ZA202102492B (en) 2024-04-24
JP2022512736A (ja) 2022-02-07
US20250115637A1 (en) 2025-04-10
JP2024150488A (ja) 2024-10-23
DK3866931T3 (da) 2023-04-24
IL282231A (en) 2021-05-31
KR20210078487A (ko) 2021-06-28
PL3866931T3 (pl) 2023-06-19
WO2020079165A1 (en) 2020-04-23
ES2942468T3 (es) 2023-06-01
AU2019362389B2 (en) 2024-12-12
KR102848971B1 (ko) 2025-08-21
IL282231B2 (en) 2025-07-01
EP3866931B1 (en) 2023-02-15
CA3116198A1 (en) 2020-04-23
SG11202103726RA (en) 2021-05-28
BR112021007060A2 (pt) 2021-07-20
FI3866931T3 (fi) 2023-05-10
HUE061801T2 (hu) 2023-08-28
CN112930214A (zh) 2021-06-08
CN112930214B (zh) 2025-05-16
EP3866931A1 (en) 2021-08-25
US12152087B2 (en) 2024-11-26
IL282231B1 (en) 2025-03-01
JP7603199B2 (ja) 2024-12-20
MX2021004474A (es) 2021-08-24
AU2019362389A1 (en) 2021-06-03

Similar Documents

Publication Publication Date Title
MA53904A (fr) Composés contenant du deutérium
IL286833A (en) Compositions containing brazzein
PL3844147T3 (pl) Związki chemiczne
EP3836923A4 (en) PYRROLO-DIPYRIDINE COMPOUNDS
MA52489A (fr) Nouveaux composés
MA52948A (fr) Composés
EP3720430A4 (en) BENZOCARBONYL COMPOUNDS
EP3802467A4 (en) SPIROCYCLIC COMPOUNDS
MA55131A (fr) Nouveaux composés hétérocycliques
EP3781156A4 (en) SPIROCYCLIC COMPOUNDS
MA51669A (fr) Composés
EP3494121A4 (en) CONTINUOUS CONNECTIONS
MA44233A (fr) Nouveaux composés
DK3692040T3 (da) Kemiske forbindelser
MA53003A (fr) Composés
MA47576A (fr) Composés inhibiteurs d'oga bicyclique
MA43512A (fr) Composés hétérocycliques utiles en tant que modulateurs du tnf alpha
EP3445750A4 (en) THERAPEUTIC COMPOUNDS
MA47420A (fr) Composés inhibiteurs d'oga
EP3315430A4 (en) CONTAINER
EP3728289A4 (en) OPTIMIZED CONNECTIONS
EP3464336A4 (en) LINKS
EP3897732A4 (en) COMPOSITION CONTAINING CANNABINOIDS
MA52946A (fr) Composés
EP4077318A4 (en) Compounds